Clinical Trials Sponsored by Vivoryon Therapeutics N.V.

Total 26 results

Vivoryon Therapeutics N.V.
Covance

Completed

Effects of PQ912 on the Pharmacokinetics of Midazolam and Omeprazole

Healthy Volunteers | Pharmacologic Action

United Kingdom
Vivoryon Therapeutics N.V.
Amsterdam UMC, location VUmc; Julius Clinical

Completed

Safety and Tolerability of PQ912 in Subjects With Early Alzheimer's Disease (SAPHIR)

Alzheimer's Disease

Spain, Finland, Germany, Netherlands, Belgium, France, Sweden
Vivoryon Therapeutics N.V.
Amsterdam UMC, location VUmc; Nordic Bioscience A/S

Completed

A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD (VIVIAD)

Early Alzheimers Disease | Mild Cognitive Impairment Due to AD

Netherlands, Spain, Denmark, Germany, Poland
Vivoryon Therapeutics N.V.
National Institute on Aging (NIA); Alzheimer's Disease Cooperative Study (ADCS)

Recruiting

A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD (VIVA-MIND)

Alzheimer Disease

United States
NorthSea Therapeutics B.V.

Completed

A Phase 1, First Time in Humans Study of NST-1024

Hypertriglyceridemia

United Kingdom
NorthSea Therapeutics B.V.

Recruiting

Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia

High Triglycerides

United States
NorthSea Therapeutics B.V.

Completed

Open-label Study to Evaluate the Effects of NST-1024 on the PK of Multiple Drugs in Healthy Subjects

Healthy Volunteers

United Kingdom
NorthSea Therapeutics B.V.

Completed

Study of NST-6179 in Healthy Subjects

Short Bowel Syndrome | Parenteral Nutrition Associated Liver Disease

United Kingdom
NorthSea Therapeutics B.V.

Active, not recruiting

A Phase 2b Study of Icosabutate in Fatty Liver Disease (ICONA)

Non Alcoholic Steatohepatitis (NASH)

United States, Puerto Rico
NorthSea Therapeutics B.V.

Completed

A Study to Evaluate the Effects of NST-4016 on QT/Corrected QT (QTc) Interval

Dyslipidemias

United Kingdom
BBB-Therapeutics B.V.

Completed

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Melanoma | Breast Cancer | Lung Cancer | Malignant Glioma | Brain Metastases

United States, Netherlands, France, Belgium
NorthSea Therapeutics B.V.

Recruiting

A Study of NST-6179 in Adult Subjects With Intestinal Failure-Associated Liver Disease (IFALD).

Intestinal Failure Associated Liver Disease

United States
BBB-Therapeutics B.V.

Terminated

Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients

Multiple Sclerosis | Healthy Volunteers

Netherlands
Impatients N.V. trading as myTomorrows
Immodulon Therapeutics Ltd

No longer available

Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer

Pancreatic Cancer | Pancreatic Cancer Stage IV | Pancreas Cancer | Pancreatic Cancer Stage III

France, United Kingdom
Flamingo Therapeutics NV

Recruiting

Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC (PEMDA-HN)

HNSCC

United States, Korea, Republic of
Orca Therapeutics B.V.
CMX Research

Active, not recruiting

First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients.

Adenocarcinoma of the Prostate

Canada
Origo Biopharma

Completed

First in Human Study of ORG-129 in Healthy Volunteers

Healthy Volunteers

Spain
CeleCor Therapeutics
Diagram B.V.; ST. Antonius hospital Nieuwegein

Completed

A Phase 2 Open Label Study to Assess the PK/PD Properties of RUC-4 in Patients With a ST-elevation Myocardial Infarction (CEL-02)

Myocardial Infarction | Heart Diseases | Vascular Diseases | Coronary Disease | STEMI - ST Elevation Myocardial Infarction

Netherlands
Agomab Spain S.L.

Recruiting

Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants With IPF

IPF

United Kingdom
Agomab Spain S.L.

Recruiting

STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease

Fibrostenotic Crohn's Disease

United States, Italy, Poland, Spain, Denmark, Austria, Canada, Germany
Agomab Spain S.L.

Completed

Drug-Drug Interaction Study With AGMB-129 and Midazolam in Healthy Participants

Healthy Volunteers

Belgium
Merus N.V.
Chiltern International Inc.; Q2 Solutions; Oncology Therapeutic Development (OTD) and other collaborators

Recruiting

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Gastric Cancer | Colorectal Cancer | NSCLC | Head and Neck Squamous Cell Carcinoma | HNSCC | Advanced/Metastatic Solid Tumors | Gastroesophageal-junction Cancer

United States, Spain, Belgium, France, Netherlands, United Kingdom
Laboratorios Silanes S.A. de C.V.
Rare Disease Therapeutics Inc.

Completed

Pharmacokinetic Study Protocol of ANAWIDOW Lyophilized Powder for Solution for Intravenous Use in Fasting Conditions

Latrodectism

Mexico
Instituto Bioclon S.A. de C.V.
Rare Disease Therapeutics Inc.

Completed

Black Widow Spider Antivenin for Patients With Systemic Latrodectism (BWSP3)

Latrodectism

United States
Montefiore Medical Center
M.D. Anderson Cancer Center; Flamingo Therapeutics NV

Recruiting

Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

Acute Myeloid Leukemia | Myelodysplastic Syndromes | AML/MDS

United States
Atriva Therapeutics GmbH
SGS Life Sciences, a division of SGS Belgium NV

Completed

Phase 1 Study of ATR-002

Influenza

Belgium

Clinical Trials Sponsored by Vivoryon Therapeutics N.V.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations